2019 MIPS Measure #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier

Measure Type High Priority Measure? Collection Type(s)
Process no MIPS CQM

Measure Description

Percentage of patients, regardless of age, with psoriasis, psoriatic arthritis and rheumatoid arthritis on a biological immune response modifier whose providers are ensuring active tuberculosis prevention either through yearly negative standard tuberculosis screening tests or are reviewing the patient’s history to determine if they have had appropriate management for a recent or prior positive test

Stay up to date with the latest news regarding MACRA and MIPS.

The Healthmonix Advisor is a free weekly news source, connecting you to the latest updates in the value-based care industry.


This measure is to be submitted a minimum of once per performance period for patients with psoriasis and/or psoriatic arthritis and/or rheumatoid arthritis seen during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Measure Submission Type:

Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.


All patients, regardless of age, with a diagnosis of psoriasis and/or psoriatic arthritis and/or rheumatoid arthritis who are on a biologic immune response modifier


Biologic Immune Response Modifier –

  1. TNF-alpha inhibitors, to include, but not limited toInfliximab (Remicade), Adalimumab (Humira), Etanercept (Enbrel), or Golimumab (Simponi), Certolizumab (Cimzia).
  2. Inhibitors of IL-12 and/or IL-23 or their receptors to include but not limited to Ustekinumab (Stelara).
  3. B7 inhibitors, to include but not limited to Abatacept (Orencia).
  4. Inhibitors of IL-17 family members or their

DENOMINATOR NOTE: A patient would be considered denominator eligible for Measure #337 for submission purposes, if the patient meets the denominator criteria with diagnosis of psoriasis or psoriatic arthritis or rheumatoid arthritis AND is on a biologic immune response modifier PRESCRIBED BY THE PROVIDER BEING EVALUATED FOR THE MEASURE.

*Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.

Examples of Applicable Medications
Brand Name Chemical Name Mechanism of Action/ Type of Biologic
Orencia abatacept Blocks T cell activation
Rituxan rituximab CD 20 directed antibody
Kineret anakinra Interleukin (IL)-1 inhibitors
Actemra tocilizumab IL-6 inhibitor
Kevzara Sarilumab IL-6 inhibitor
Stelara ustekinumab IL-12 and IL-23 inhibitors
Cosentyx secukinumab IL-17 inhibitors
Siliq brodalumab IL-17 inhibitors
Taltz ixekizumab IL-17 inhibitors
Tremfya guselkumab IL-23 inhibitors
Ilumya Tildrakizumab Selective (IL)-23p19 inhibitor
Amjevita adalimumab-atto TNF-alpha inhibitors
Cimzia certolizumab TNF-alpha inhibitors
Cyltezo adalimumab-adbm TNF-alpha inhibitors
Enbrel etanercept TNF-alpha inhibitors
Erelzi etanercept-szzs TNF-alpha inhibitors
Humira adalimumab TNF-alpha inhibitors
Inflectra infliximab-dyyb TNF-alpha inhibitors
Remicade infliximab TNF-alpha inhibitors
Renflexis infliximab-abda TNF-alpha inhibitors
Simponi and Simponi Aria golimumab TNF-alpha inhibitors

Denominator Criteria (Eligible Cases):

All patients, regardless of age


Diagnosis for psoriasis (ICD-10-CM): L40.0, L40.1, L40.2, L40.3, L40.4, L40.8, L40.9


Diagnosis for psoriatic arthritis (ICD-10-CM): L40.50, L40.51, L40.52, L40.53, L40.54, L40.59


Diagnosis for rheumatoid arthritis (ICD-10-CM): M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, M05.129, M05.131, M05.132, M05.139, M05.141, M05.142, M05.149, M05.151, M05.152, M05.159, M05.161, M05.162, M05.169, M05.171, M05.172, M05.179, M05.19, M05.20, M05.211, M05.212, M05.219, M05.221, M05.222, M05.229, M05.231, M05.232, M05.239, M05.241, M05.242, M05.249, M05.251, M05.252, M05.259, M05.261, M05.262, M05.269, M05.271, M05.272, M05.279, M05.29, M05.30, M05.311, M05.312, M05.319, M05.321, M05.322, M05.329, M05.331, M05.332, M05.339, M05.341, M05.342, M05.349, M05.351, M05.352, M05.359, M05.361, M05.362, M05.369, M05.371, M05.372, M05.379, M05.39, M05.40, M05.411, M05.412, M05.419, M05.421, M05.422, M05.429, M05.431, M05.432, M05.439, M05.441, M05.442, M05.449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.479, M05.49, M05.50, M05.511, M05.512, M05.519, M05.521, M05.522, M05.529, M05.531, M05.532, M05.539, M05.541, M05.542, M05.549, M05.551, M05.552, M05.559, M05.561, M05.562, M05.569, M05.571, M05.572, M05.579, M05.59, M05.60, M05.611, M05.612, M05.619, M05.621, M05.629, M05.631, M05.632, M05.639, M05.641, M05.642, M05.649, M05.651, M05.652, M05.659, M05.661, M05.662, M05.669, M05.671, M05.672, M05.679, M05.69, M05.70, M05.711, M05.712, M05.719, M05.721, M05.722, M05.729, M05.731, M05.732, M05.739, M05.741, M05.742, M05.749, M05.751, M05.752, M05.759, M05.761, M05.762, M05.769, M05.771, M05.772, M05.779, M05.79, M05.80, M05.811, M05.812, M05.819, M05.821, M05.822, M05.829, M05.831, M05.832, M05.839, M05.841, M05.842, M05.849, M05.851, M05.852, M05.859, M05.861, M05.862, M05.869, M05.871, M05.872, M05.879, M05.89, M05.9, M06.00, M06.011, M06.012, M06.019, M06.021, M06.022, M06.029, M06.031, M06.032, M06.039, M06.041, M06.042, M06.049, M06.051, M06.052, M06.059, M06.061, M06.062, M06.069, M06.071, M06.072, M06.079, M06.08, M06.09, M06.1, M06.20, M06.211, M06.212, M06.219, M06.221, M06.222, M06.229, M06.231, M06.232, M06.239, M06.241, M06.242, M06.249, M06.251, M06.252, M06.259, M06.261, M06.262, M06.269, M06.271, M06.272, M06.279, M06.28, M06.29, M06.30, M06.311, M06.312, M06.319, M06.321, M06.322, M06.329, M06.331, M06.332, M06.339, M06.341, M06.342, M06.349, M06.351, M06.352, M06.359, M06.361, M06.362, M06.369, M06.371, M06.372, M06.379, M06.38, M06.39, M06.80, M06.811, M06.812, M06.819, M06.821, M06.822, M06.829, M06.831, M06.832, M06.839, M06.841, M06.842, M06.849, M06.851, M06.852, M06.859, M06.861, M06.862, M06.869, M06.871, M06.872, M06.879, M06.88, M06.89, M06.9


Patient encounter during performance period (CPT or HCPCS): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241*, 99242*, 99243*, 99244*, 99245*, G0402


Telehealth Modifier: GQ, GT, 95, POS 02


Biologic immune response modifier prescribed: G9506


Patients who have a documented negative annual TB screening or have documentation of the management of a positive TB screening test with no evidence of active tuberculosis, confirmed through use of radiographic imaging (i.e., chest x-ray, CT)


Documentation – To satisfy this measure, documentation will incorporate the following:

  • Initials of the clinician that prescribed the biologic
  • Initials of clinician that administered the TB test
  • Initials of the clinician that performed the skin test evaluating the results note in the medical record that results are negative OR that results are positive and is confirmed via results from radiographic imaging (chest x-ray, CT)

If TB test is administered by a provider other than the biologic prescriber, confirmation of the above mentioned must be obtained via letter or other written means from the administering provider.

NUMERATOR NOTE: For Denominator Exception(s): patients are ineligible for this measure if at the time of follow-up there are patient reason(s) for not documenting TB test results (e.g. patient did not return for Mantoux (PPD) skin test evaluation).

Numerator Options:

Performance Met: Documentation of negative or managed positive TB screen with further evidence that TB is not active within one year of patient visit (G9359)


Denominator Exception: Documentation of patient reasons(s) for not having records of negative or managed positive TB screen (e.g., patient does not return for Mantoux (PPD) skin test evaluation) (G9932)


Performance Not Met: No documentation of negative or managed positive TB screen (G9360)


CMS-Dermatology-2019, CMS-Family-Medicine-2019, CMS-Internal-Medicine-2019, Dermatology, General Practice/Family Medicine, Geriatrics / Gerontology, Hand Surgery, Internal Medicine, Orthopedics, Pediatrics, Quality-2019, Rheumatology